Basal cell carcinoma: A comprehensive review of existing and emerging nonsurgical therapies

Journal of Clinical and Aesthetic Dermatology

Volumn 9, Issue 5, 2016, Pages 26-36

  Lanoue, Julien ^a   Goldenberg, Gary ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; SOLASODINE; TAZAROTENE; VISMODEGIB;

BASAL CELL CARCINOMA; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CARBON DIOXIDE LASER; CONSERVATIVE TREATMENT; CONTINUOUS WAVE LASER; ERBIUM YAG LASER; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LOW LEVEL LASER THERAPY; PHOTODYNAMIC THERAPY; REVIEW; SYSTEMIC THERAPY; TELETHERAPY;

EID: 84969277649     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Bulliard JL, Panizzon RG, Levi F. Epidemiology of epithelial skin cancers. Rev Med Suisse. 2009;5(200):882-884-8.
2. Koh D, Wang H, Lee J, et al. Basal cell carcinoma, squamous cell carcinoma and melanoma of the skin: Analysis of the Singapore Cancer Registry. Br J Dermatol. 2003;148:1161-1166.
3. Mohan S, Chang AL. Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations. Curr Derm Rep. 2014;3:40-45.
4. Scotto J, Fears TR, Fraumeni JF Jr, et al. Incidence of nonmelanoma skin cancer in the United States in collaboration with Fred Hutchinson Cancer Research Center. NIH publication No. 83-2433, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, Bethesda, MD 1983:xv. p.113.
5. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283-287.
6. Tran H, Chen K, Shumack S. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2003;149:50-52.
7. Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol. 1999;135:781.
8. Marks R, Staples M, Giles GG. Trends in non-melanocytic skin cancer treated in Australia: The second national survey. Int J Cancer. 1993;53:585.
9. Demers AA, Nugent Z, Mihalcioiu C, et al. Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol. 2005;53:320.
10. Kim RH, Armstrong AW. Nonmelanoma skin cancer. Dermatol Clin. 2012;30(1):125-139, ix.8.
11. Wu TP, Stein JA. Nonmelanoma skin cancer in young women. J Drugs Dermatol. 2013;12(5):568-572.9.
12. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294(6):681-690.
13. Gaulin C, Sebaratnam DF, Fernández-Peñas P. Quality of life in non-melanoma skin cancer. Australas J Dermatol. 2015;56(1):70-76.
14. Chren MM, Sahay AP, Bertenthal DS, et al. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2007;127(6):1351-1357.
15. Cakir BO, Adamson P, Cingi C. Epidemiology and economic burden of non-melanoma skin cancer. Facial Plast Surg Clin North Am. 2012;20(4):419-422.
16. Chen JG, Fleischer AB Jr, Smith ED, et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg. 2001;27(12):1035-1038.1.
17. Lo JS, Snow SN, Reizner GT, et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24(5 Pt 1):715-719.
18. Kyrgidis A, Vahtsevanos K, Tzellos TG, et al. Clinical, histological and demographic predictors for recurrence and second primary tumours of head and neck basal cell carcinoma. A 1062 patientcohort study from a tertiary cancer referral hospital. Euro J Dermatol. 2010;20(3):276-282.
19. Dourmishev LA, Rusinova D, Botev I. Clinical variants, stages, and management of basal cell carcinoma. Indian Dermatol Online J. 2013;4(1):12-17.
20. Chren MM, Linos E, Torres JS, et al. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2013;133(5):1188-1196.
21. Silverman MK, Kopf AW, Bart RS, et al. Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol. 1992;18(6):471-476.
22. Botto N, Rogers G. Nontraditional management of basal cell carcinoma. J Drugs Dermatol. 2013;12(5):525-532.
23. Goldenberg G, Hamid O. Nonsurgical treatment options for basal cell carcinoma-focus on advanced disease. J Drugs Dermatol. 2013;12(12):1369-1378.
24. Bilu D, Sauder DN. Imiquimod: modes of action. Br J Dermatol. 2003;149 Suppl 66:5-8.
25. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003;139(10):1325-1332.
26. Wolff F, Loipetzberger A, Gruber W, et al. Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene. 2013;32(50):5574-5581.
27. Aldara (imiquimod) cream 5% [package insert]. St Paul, MN: 3M Pharmaceuticals; 2004.
28. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722-733.
29. Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: A systematic review and meta-Analysis of randomized and nonrandomized trials. Br J Dermatol. 2012;167(4):733-756.
30. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-Term follow-up study in Europe. Eur J Dermatol. 2008;18(6):677-682.
31. Quirk C, Gebauer K, DeAmbrosis B, et al. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis. 2010;85(6): 318-324.
32. Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007;57(4):616-621.
33. Garcia-Martin E, Idoipe M, Gil LM, et al. Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas. J Ocul Pharmacol Ther. 2010;26(4):373-379.
34. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week openlabel trial. Dermatol Surg. 2005;31(3):318-323.
35. Prokosch V, Thanos S, Spaniol K, Stupp T. Long-Term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids. Graefes Arch Clin Exp Opthalmol. 2011;249(1):121-125.
36. Schumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dos-ing regimens. Arch Dermatol. 2002;138(9):1165-1171.
37. Van der geer S, Martens J, Van roij J, et al. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: A prospective randomized controlled study. Br J Dermatol. 2012;167(1):110-115.
38. Wu JK, Oh C, Strutton G, Siller G. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol. 2006;47(1):46-48.
39. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006;32(1):63-69.
40. Vidal D, Matías-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol. 2007;143(2):266-268.
41. Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): A multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(1):96-105.
42. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treat-ment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939-947.
43. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47(3):390-398.
44. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: A systematic review. Arch Dermatol. 2009;145(12):1431-1438.
45. Dreier J, Felderer L, Barysch M, et al. Basal cell carcinoma: A paradigm for targeted therapies. Expert Opin Pharmacother. 2013;14(10):1307-1318.
46. Mohs FE, Jones DL, Bloom RF. Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol. 1978;114(7):1021-1022.
47. Klostermann GF. Effects of 5-fluorouracil (5-FU) ointment on normal and diseased skin. Histological findings and deep action. Dermatologica. 1970;140:(Suppl 1):47-54.
48. Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. Dermatologica. 1979;158(5):368-372.
49. Romagosa R, Saap L, Givens M, et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol Surg. 2000;26(4):338-340.
50. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: A single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14:647-654.
51. Efudex (fluorouracil) cream 5% [package insert]. Aliso Viejo, CA: Valeant Pharmaceuticals International; 2005.
52. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33(4):433-439.
53. Miller BH, Shavin JS, Cognetta A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol. 1997;36(1):72-77.
54. Orenberg EK, Miller BH, Greenway HT, et al. The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma. J Am Acad Dermatol. 1992;27(5 Pt 1):723-728.
55. Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol. 1985;121(2):207-213.
56. Micali G, Lacarrubba F, Bhatt K, Nasca MR. Medical approaches to non-melanoma skin cancer. Expert Rev Anticancer Ther. 2013;13(12):1409-1421.
57. Johnson MR, Hageboutros A, Wang K, et al. Life-Threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5(8):2006-2011.
58. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010-1019.
59. Micali G, Lacarrubba F, Nasca MR, Schwartz RA. Topical pharmacotherapy for skin cancer: part I. Pharmacology. J Am Acad Dermatol. 2014;70(6):965.e1-12.
60. Siller G, Rosen R, Freeman M, et al. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51(2):99-105.
61. Duvic M, Nagpal S, Asano AT, Chandraratna RA. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997;37(2 Pt 3):S18-S24.
62. Wu CS, Chen GS, Lin PY, et al. Tazarotene induces apoptosis in human basal cell carcinoma via activation of caspase-8/t-Bid and the reactive oxygen species-dependent mitochondrial pathway. DNA Cell Biol. 2014;33(10):652-666.
63. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med. 1999;341:1767-1768.
64. Bianchi L, Orlandi A, Campione E, et al. Topical treatment of basal cell carcinoma with tazarotene: A clinicopathological study on a large series of cases. Br J Dermatol. 2004;151(1):148-156.
65. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007;(1):CD003412.
66. Punjabi S, Cook LJ, Kersey P, et al. Solasodine glycoalkaloids: A novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study. Int J Dermatol. 2008;47(1):78-82.
67. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B Biol. 1990;6(1-2):143-148.
68. Oseroff A. PDT as a cytotoxic agent and biological response modifier: Implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol. 2006;126(3):542-544.
69. Wilson BD, Mang TS, Stoll H, Jones C, Cooper M, Dougherty TJ. Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol. 1992;128:1597-1601.
70. Lui H, Hobbs L, Tope WD, et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: Two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol. 2004;140(1):26-32.
71. Köbler AC, Haase T, Staff C, et al. J. Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck. Lasers Surg Med. 1999;25(1):60-68.
72. Baas P, Saarnak AE, Oppelaar H, et al. Photodynamic therapy with meta-Tetrahydroxyphenylchlorin for basal cell carcinoma: A phase I/II study. Br J Dermatol. 2001;145(1):75-78.
73. Peng Q, Soler AM, Warloe T, et al. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-Aminolevulinate. J Photochem Photobiol B Biol. 2001;62(3):140-145.
74. Kuijpers DI, Thissen MR, Thissen CA, Neumann MH. Similar effectiveness of methyl aminolevulinate and 5-Aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol. 2006;5(7):642-645.
75. De Vijlder HC, Sterenborg HJ, Neumann HA, et al. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Derm Venereol. 2012;92(6):641-647.
76. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: A 5 year randomized trial. Eur J Dermatol. 2008;18(5):547-553.
77. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol. 2003;149(6):1242-1249.
78. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs. surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143(9):1131-1136.
79. Roozeboom MH, Aardoom MA, Nelemans PJ, et al. Fractionated 5-Aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: A randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol. 2013;69(2):280-287.
80. Lien MH, Sondak VK. Nonsurgical treatment options for Basal cell carcinoma. J Skin Cancer. 2011;2011:571734.
81. Itkin A, Gilchrest BA. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. Dermatol Surg. 2004;30(7):1054-1061.
82. Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-Aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol. 2008;159(4): 864-870.
83. Ormerod A, Rajpara S, Craig F. Basal cell carcinoma. BMJ Clin Evid. 2010 Apr 6.
84. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol. 2002;146(4):552-567.
85. Choudhary S, Tang J, Elsaie ML, Nouri K. Lasers in the treatment of nonmelanoma skin cancer. Dermatol Surg. 2011;37(4): 409-425.
86. Campolmi P, Brazzini B, Urso C, et al. Superpulsed CO2 laser treatment of basal cell carcinoma with intraoperatory histopathologic and cytologic examination. Dermatol Surg. 2002;28(10):909-911.
87. Horlock N, Grobbelaar AO, Gault DT. Can the carbon dioxide laser completely ablate basal cell carcinomas? A histological study. Br J Plast Surg. 2000;53(4):286-293.
88. Moskalik K, Kozlov A, Demin E, et al. The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd:YAG lasers. Photomed Laser Surg. 2009;27(2):345-349.
89. Karsai S, Friedl H, Buhck H, et al. The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: outcome of a double-blind randomized placebo-controlled trial. Br J Dermatol. 2015;172(3):677-683.
90. Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment. Lasers Surg Med. 2011;43(2):72-78.
91. Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med. 2008;40(2):153-158.
92. Locke J, Karimpour S, Young G, et al. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):748-755.
93. Hall VL, Leppard BJ, McGill J, et al. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol. 1986;37(1):33-34.
94. Alam M, Nanda S, Mittal BB, et al. The use of brachytherapy in the treatment of nonmelanoma skin cancer: A review. J Am Acad Dermatol. 2011;65(2):377-388.
95. Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997;76:100-106.
96. Guix B, Finestres F, Tello J, et al. Treatment of skin carcinomas of the face by high-dose-rate brachytherapy and custom-made surface molds. Int J Radiat Oncol Biol Phys. 2000;47(1):95-102.
97. Debois J. Cesium-137 brachytherapy for epithelioma of the skin of the nose: experience with 370 patients. J Belge Radiol. 1994;77:1-4.
98. Xoft, Inc. Available at: http://www.xoftinc.com/blog/. Accessed December 31, 2014.
99. Bhatnagar A. Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year. Brachytherapy. 2013;12(2): 134-140.
100. Petit JY, Avril MF, Margulis A, et al. Evaluation of cosmetic results of a random-ized trial comparing surgery and radiotherapy in the treat-ment of basal cell carcinoma of the face. Plast Reconstr Surg. 2000;105:2544-2551.
101. Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol. 1998;110(6):885-888.
102. Epstein EH. Basal cell carcinomas: Attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743-754.
103. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
104. Hutchin ME, Kariapper MS, Grachtchouk M, et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2005;19(2): 214-223.
105. Lo M. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. 2008;3:32.
106. Sekulic A, Schadendorf D, Solomon J, et al. Long-Term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. J Am Acad Dermatol. 2014;70(5):AB137.
107. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol. 2012;148(11):1324-1325.
108. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180-2188.
109. Ally MS, Aasi S, Wysong A, et al. An investigator-initiated openlabel clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):904-911.e1.
110. Sofen H, Peale F, Sharata H, et al. Efficacy and safety of vismodegib in operable basal cell carcinoma: Final results of a phase 2 trial. J Am Acad Dermatol. 2014;70(5):AB135.
111. Graham RA, Hop CE, Borin MT, et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol. 2012;74(5):788-796.
112. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60-69.
113. Ali FR, Lear JT. Systemic treatments for basal cell carcinoma (BCC): The advent of dermato-oncology in BCC. Br J Dermatol. 2013;169(1):53-57.
114. Migden M, Guminksi A. Randomized, double-blind study of sonidegib (LDE225) in patients with locally advanced or metastatic basal-cell carcinoma. J Clin Oncol. 2014;32(5): AB9009a.
115. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131(8): 1735-1744.
116. Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745-751.
117. Dreier J, Dummer R, Felderer L, et al. Emerging drugs and combination strategies for basal cell carcinoma. Expert Opin Emerg Drugs. 2014;19(3):353-365.
118. Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: A summary of published cases from 1981 through 2011. JAMA Dermatol. 2013;149(5):615-616.
119. Wieman TJ, Shively EH, Woodcock TM. Responsiveness of metastatic basal-cell carcinoma to chemotherapy. A case report. Cancer. N1983;52(9):1583-1585.
120. Coker DD, Elias EG, Viravathana T, et al. Chemotherapy for metastatic basal cell carcinoma. Arch Dermatol. 1983;119(1): 44-50.
121. Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985;55(8):1629-1632.
122. Bason MM, Grant-Kels JM, Govil M. Metastatic basal cell carcinoma: response to chemotherapy. J Am Acad Dermatol. 1990;22(5 Pt 2):905-908.
123. Khandekar JD. Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: A report of two patients. Arch Dermatol. 1990;126(12):1, 660.
124. Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999;22(1):32-34.
125. Jefford M, Kiffer JD, Somers G, et al. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004;74(8):704-705.
126. Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma-A review of the literature. Acta Oncol. 1996;35(6):677-682.
127. Carneiro BA, Watkin WG, Mehta UK, Brockstein BE. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 2006;24(4)396-400.